SUBSCRIBE
SUBSCRIBE
News   Drug Development

Study Shows Teva Pharmaceutical Industries Limited’s Laquinimod Slows MS

June 20, 2008 | 
1 min read
LONDON, June 20 (Reuters) - Teva Pharmaceutical Industries' multiple sclerosis pill laquinimod appears to slow the disease and is well-tolerated by people with the relapsing form of the incurable condition, researchers said on Friday.
Clinical research Phase 2 Europe
MORE ON THIS TOPIC
Strategy for company development concept. Employees conduct comparative analysis to improve their work. Competitiveness of business. Cartoon flat vector illustration isolated on blue background
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
April 28, 2026
 · 
2 min read
 · 
Heather McKenzie
The path to precision. The road to the center of the target. The concept of goal achievement, precision, strategic direction, and focus on results. Polygonal design, blue background.
Deals
Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’
April 28, 2026
 · 
2 min read
 · 
Gabrielle Masson
Crossed fingers and polygraph. Dishonesy, fake news, manipulation concept. Vector illustration.
Regulatory
FDA alleges ‘manipulated’ data supported approval of Amgen’s autoimmune drug
April 28, 2026
 · 
2 min read
 · 
Tristan Manalac
man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top
Pancreatic cancer
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
April 28, 2026
 · 
3 min read
 · 
Tristan Manalac